Compare BGSF & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BGSF | LUNG |
|---|---|---|
| Founded | 2007 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.4M | 72.2M |
| IPO Year | 2013 | 2020 |
| Metric | BGSF | LUNG |
|---|---|---|
| Price | $6.07 | $1.36 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $9.00 | $5.38 |
| AVG Volume (30 Days) | 24.1K | ★ 680.2K |
| Earning Date | 03-11-2026 | 03-04-2026 |
| Dividend Yield | ★ 32.36% | N/A |
| EPS Growth | ★ 67.37 | 7.64 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $272,499,000.00 | $90,497,000.00 |
| Revenue This Year | $4.67 | $6.20 |
| Revenue Next Year | N/A | $21.61 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 8.01 |
| 52 Week Low | $2.91 | $1.31 |
| 52 Week High | $8.20 | $7.97 |
| Indicator | BGSF | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 54.39 | 37.62 |
| Support Level | $5.93 | N/A |
| Resistance Level | $6.38 | $2.01 |
| Average True Range (ATR) | 0.26 | 0.17 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 39.77 | 5.29 |
BGSF Inc is a national provider of consulting, managed services, and professional workforce solutions. two segments: Property Management and Professional. In the Property Management segment is a provider of office and maintenance talent. The Professional segment provides IT professionals with expertise in SAP, Workday, Peoplesoft, Hyperion, Oracle, One Stream, cyber, project management, managed services, and other IT workforce solutions to client partners on a national basis. The group generates the majority of its revenue from the Professional segment.
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.